NASDAQ:ARAV Aravive - ARAV Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aravive, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.74 +0.05 (+2.66%) (As of 01/31/2023 11:12 AM ET) Add Compare Share Share Today's Range$1.68▼$1.7450-Day Range$1.20▼$1.8352-Week Range$0.58▼$2.40Volume15,828 shsAverage Volume100,551 shsMarket Capitalization$103.81 millionP/E RatioN/ADividend YieldN/APrice Target$7.25 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Aravive MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside385.2% Upside$8.20 Price TargetShort InterestHealthy1.70% of Shares Sold ShortDividend StrengthN/ASustainability-0.83Upright™ Environmental ScoreNews Sentiment0.27Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.99) to ($1.34) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.53 out of 5 starsMedical Sector155th out of 1,055 stocksPharmaceutical Preparations Industry67th out of 518 stocks 3.5 Analyst's Opinion Consensus RatingAravive has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.20, Aravive has a forecasted upside of 385.2% from its current price of $1.69.Amount of Analyst CoverageAravive has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.70% of the outstanding shares of Aravive have been sold short.Short Interest Ratio / Days to CoverAravive has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aravive has recently increased by 23.32%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAravive does not currently pay a dividend.Dividend GrowthAravive does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAravive has received a 74.23% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Aravive is -0.83. Previous Next 2.9 News and Social Media Coverage News SentimentAravive has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Aravive this week, compared to 1 article on an average week.Search Interest6 people have searched for ARAV on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows7 people have added Aravive to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aravive insiders have not sold or bought any company stock.Percentage Held by Insiders60.00% of the stock of Aravive is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 16.85% of the stock of Aravive is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Aravive are expected to grow in the coming year, from ($1.99) to ($1.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aravive is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aravive is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAravive has a P/B Ratio of 0.84. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Aravive (NASDAQ:ARAV) StockAravive, Inc. operates as a clinical stage biotechnology company. The firm engages in the development of new therapies that target important survival pathways for both advanced solid tumors as well as hematologic malignancies. Its product candidate, Aravive-S6, is a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL which also promotes metastasis, cancer cell survival, resistance to treatments and immune suppression. The company was founded on December 10, 2008 and is headquartered in Houston, TX.Read More Receive ARAV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aravive and its competitors with MarketBeat's FREE daily newsletter. Email Address ARAV Stock News HeadlinesJanuary 31, 2023 | americanbankingnews.comCritical Review: Medicure (OTCMKTS:MCUJF) vs. Aravive (NASDAQ:ARAV)January 30, 2023 | americanbankingnews.comAravive, Inc. (NASDAQ:ARAV) Short Interest Up 23.3% in JanuaryJanuary 31, 2023 | PressReach (Ad)Top Lithium StockToday's stock market report features a battery metal lithium stock with great potential.January 27, 2023 | finance.yahoo.comWhile individual investors own 25% of Aravive, Inc. (NASDAQ:ARAV), private equity firms are its largest shareholders with 50% ownershipJanuary 4, 2023 | finance.yahoo.comAravive Announces Complete Enrollment in the Global Registrational Phase 3 AXLerate-OC Trial for Platinum-Resistant Ovarian CancerDecember 14, 2022 | seekingalpha.comAravive: Down But Not Out With Pivotal Ovarian Data Due In 2023November 29, 2022 | finance.yahoo.comAravive Announces Fast Track Designation of Batiraxcept for Treatment of ccRCCNovember 21, 2022 | finance.yahoo.comAravive To Participate in Piper’s 34th Annual Healthcare ConferenceJanuary 31, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.November 16, 2022 | finance.yahoo.comAravive Regains Compliance with Nasdaq Minimum Bid Price RequirementOctober 25, 2022 | finance.yahoo.comAravive Announces Approximately $41.5 Million Private Placement FinancingOctober 24, 2022 | finance.yahoo.comHere's Why We're A Bit Worried About Aravive's (NASDAQ:ARAV) Cash Burn SituationOctober 10, 2022 | finance.yahoo.comAravive Receives Third Development Milestone from 3D MedicinesOctober 5, 2022 | globenewswire.comMetastatic Renal Cell Carcinoma Clinical Trials Pipeline Landscape Analysis of 45+ Companies by DelveInsight - GlobeNewswireSeptember 26, 2022 | benzinga.comAravive to Participate in the Cantor Fitzgerald Oncology & HemOnc Conference - Aravive (NASDAQ:ARAV) - BenzingaSeptember 26, 2022 | finance.yahoo.comAravive to Participate in the Cantor Fitzgerald Oncology & HemOnc ConferenceSeptember 22, 2022 | uk.investing.comWhy SOBR Safe Shares Surged Around 233%; Here Are 68 Biggest Movers From Yesterday By Benzinga - Investing.com UKSeptember 20, 2022 | benzinga.comWhy Virios Therapeutics Is Trading Lower By 75%, Here Are 44 Stocks Moving In Tuesday’s Mid-Day Session - - BenzingaSeptember 10, 2022 | uk.investing.comWhy Zscaler Is Trading Higher By Around 19%, Here Are 44 Stocks Moving In Friday's Mid-Day Session By Benzinga - Investing.com UKSeptember 9, 2022 | benzinga.comAravive (NASDAQ:ARAV) – Aravive Reports First Quarter 2022 Financial Results and Provides Corporate Updat - BenzingaSeptember 8, 2022 | msn.comAravive Earnings Perspective: Return On Capital EmployedSeptember 6, 2022 | benzinga.com(ARAV) – Aravive Earnings Perspective: Return On Capital Employed - BenzingaSeptember 6, 2022 | globenewswire.comAravive to Participate in H.C. Wainwright 24th Annual - GlobeNewswireSeptember 6, 2022 | finance.yahoo.comAravive to Participate in H.C. Wainwright 24th Annual Global Investment ConferenceAugust 30, 2022 | reuters.comARAV.OQ - Aravive Inc | Stock Price & Latest News | ReutersAugust 12, 2022 | globenewswire.comAravive Reports Second Quarter 2022 Financial Results and Provides Corporate Updates - GlobeNewswireAugust 12, 2022 | finance.yahoo.comAravive Reports Second Quarter 2022 Financial Results and Provides Corporate Updates - Yahoo FinanceSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ARAV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aravive and its competitors with MarketBeat's FREE daily newsletter. Email Address ARAV Company Calendar Last Earnings11/10/2022Today1/31/2023Next Earnings (Estimated)3/30/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ARAV CUSIPN/A CIK1513818 Webwww.aravive.com Phone(936) 355-1910FaxN/AEmployees17Year FoundedN/APrice Target and Rating Average Stock Price Forecast$8.20 High Stock Price Forecast$12.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+317.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-39,150,000.00 Net Margins-695.57% Pretax Margin-695.57% Return on Equity-190.16% Return on Assets-100.35% Debt Debt-to-Equity RatioN/A Current Ratio1.59 Quick Ratio1.59 Sales & Book Value Annual Sales$7.44 million Price / Sales13.95 Cash FlowN/A Price / Cash FlowN/A Book Value$2.01 per share Price / Book0.86Miscellaneous Outstanding Shares59,830,000Free Float23,931,000Market Cap$103.81 million OptionableOptionable Beta2.31 Key ExecutivesGail Frances McIntyrePresident, Chief Executive Officer & DirectorLeonard Scott DoveChief Operating OfficerRudy C. HowardChief Financial & Accounting OfficerRobert B. GellerChief Medical OfficerAmy FrankeVice President-Clinical OperationsKey CompetitorsAnnovis BioNYSE:ANVSvTv TherapeuticsNASDAQ:VTVTInflaRxNASDAQ:IFRXBeyondSpringNASDAQ:BYSIAtossa TherapeuticsNASDAQ:ATOSView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 33,367 shares on 11/15/2022Ownership: 1.389%BlackRock Inc.Sold 10,802 shares on 11/15/2022Ownership: 0.586%Two Sigma Advisers LPSold 35,333 shares on 11/15/2022Ownership: 0.141%View All Institutional Transactions ARAV Stock - Frequently Asked Questions Should I buy or sell Aravive stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aravive in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ARAV shares. View ARAV analyst ratings or view top-rated stocks. What is Aravive's stock price forecast for 2023? 5 Wall Street analysts have issued 12 month price targets for Aravive's stock. Their ARAV share price forecasts range from $2.00 to $12.00. On average, they anticipate the company's share price to reach $8.20 in the next twelve months. This suggests a possible upside of 385.2% from the stock's current price. View analysts price targets for ARAV or view top-rated stocks among Wall Street analysts. How have ARAV shares performed in 2023? Aravive's stock was trading at $1.32 at the beginning of 2023. Since then, ARAV shares have increased by 28.0% and is now trading at $1.69. View the best growth stocks for 2023 here. Are investors shorting Aravive? Aravive saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 1,020,000 shares, an increase of 23.3% from the December 31st total of 827,100 shares. Based on an average daily volume of 621,800 shares, the short-interest ratio is presently 1.6 days. View Aravive's Short Interest. When is Aravive's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023. View our ARAV earnings forecast. How were Aravive's earnings last quarter? Aravive, Inc. (NASDAQ:ARAV) posted its quarterly earnings results on Thursday, November, 10th. The company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.13. The firm had revenue of $4.96 million for the quarter, compared to the consensus estimate of $1.24 million. Aravive had a negative net margin of 695.57% and a negative trailing twelve-month return on equity of 190.16%. What other stocks do shareholders of Aravive own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aravive investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Applied Genetic Technologies (AGTC), Flexion Therapeutics (FLXN), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), Arbutus Biopharma (ABUS) and BioCryst Pharmaceuticals (BCRX). What is Aravive's stock symbol? Aravive trades on the NASDAQ under the ticker symbol "ARAV." Who are Aravive's major shareholders? Aravive's stock is owned by many different institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Amato Giaccia, Gail Frances Mcintyre and Vinay Shah. View institutional ownership trends. How do I buy shares of Aravive? Shares of ARAV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Aravive's stock price today? One share of ARAV stock can currently be purchased for approximately $1.69. How much money does Aravive make? Aravive (NASDAQ:ARAV) has a market capitalization of $101.11 million and generates $7.44 million in revenue each year. The company earns $-39,150,000.00 in net income (profit) each year or ($2.36) on an earnings per share basis. How can I contact Aravive? Aravive's mailing address is River Oaks Tower 3730 Kirby Drive Suite 1200, Houston TX, 77098. The official website for the company is www.aravive.com. The company can be reached via phone at (936) 355-1910 or via email at christina@sternir.com. This page (NASDAQ:ARAV) was last updated on 1/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.